US20020041884A1 - Adenovirus formulations - Google Patents

Adenovirus formulations Download PDF

Info

Publication number
US20020041884A1
US20020041884A1 US09/799,937 US79993701A US2002041884A1 US 20020041884 A1 US20020041884 A1 US 20020041884A1 US 79993701 A US79993701 A US 79993701A US 2002041884 A1 US2002041884 A1 US 2002041884A1
Authority
US
United States
Prior art keywords
formulation
virus
concentration
range
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/799,937
Other languages
English (en)
Inventor
Robert Evans
David Volkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/799,937 priority Critical patent/US20020041884A1/en
Publication of US20020041884A1 publication Critical patent/US20020041884A1/en
Priority to US10/791,503 priority patent/US7351415B2/en
Priority to US11/071,095 priority patent/US7456009B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications.
  • Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration.
  • These formulations may comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or chelating agent to inhibit free radical oxidation.
  • An especially preferred stabilized virus formulation disclosed herein is a formulation based on inclusion of one or a combination of excipients that inhibit free radical oxidation, which are shown herein to increase stability of adenovirus formulations over commercially acceptable periods of time in about the 2-8° C. range.
  • Adenovirus vectors are currently considered one of the leading approaches for gene delivery/therapy. Because of the great potential for adenoviruses in the field of gene therapy, there remains a need for virus formulations that are suitable for human parenteral use, and have a 1-2 year shelf-life at 2-8° C. Although the U.S. military has developed live adenovirus vaccines for human use, they were lyophilized formulations delivered as oral dosage forms in enteric coated capsules (Chanock, et al., 1966, J. Am. Med. Assoc.
  • WO99/41416 discloses virus formulations which contain glycerol, sodium phosphate, Tris, sucrose, MgCl 2 , and polysorbate 80. The most stable formulation reported lost 0.52 logs of infectivity in one year at 4C.
  • WO98/02522 discloses virus formulations with concentrations of sucrose from about 0.75M to 1.5M sucrose. Such a formulation would not be acceptable for human parenteral use.
  • the present invention relates to stabilized virus formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications.
  • a preferred viral formulation may related to liquid formulations which comprise a recombinant adenovirus, formulations which show improved viral stability when stored in about the 2-8° C. range and higher while also being compatible with parenteral administration. These formulations may comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as additional components which enhance stability of the included virus, including but not limited to a free radical scavenger and/or a chelating agent.
  • the adenoviral-based formulations of the present invention are amenable to prolonged storage at 2° C. to 8° C.
  • the recombinant viruses of the present invention which show enhanced storage stability include but are not limited to adenovirus, adeno-associated virus, retroviruses, herpes virus, vaccinia virus, rotovirus, pox viruses.
  • the preferred virus is an adenovirus, including but not limited to human Ad5, Ad2, Ad6, Ad24 serotypes, and especially recombinant adenoviral virus for use in human gene therapy or human gene-based vaccination technology, including a prophylactic or therapeutic application utilizing such a gene-based vaccination technology.
  • the formulations of the present invention are (i) optimally a buffered solution and further comprise (ii) a minimal amount of at least one non-ionic surfactant; (iii) a divalent cation; (iv) a cryoprotectant; (v) a salt, and (vi), preferably inclusion of one or more additional excipients that act as inhibitors of free radical oxidation.
  • the formulations of the present invention rely on a useful range of total osmolarity which promotes long term stability at temperatures of 2-8° C., or higher, while also making the formulation useful for parenteral, and especially intramuscular, injection.
  • a first embodiment of the present invention relates to a series of adenovirus formulations (including but not limited to a recombinant adenovirus) which comprise Tris as the buffer, sucrose as the cryoprotectant, NaCl as the salt, MgCl 2 as the divalent cation and either Polysorbate-80 or Polysorbate-40 as the surfactant.
  • adenovirus formulations including but not limited to a recombinant adenovirus
  • a second embodiment of the present invention relates to inclusion of one or more inhibitors of free radical oxidation, including both metal ion chelators and hydroxyl radical scavengers, which are shown herein to enhance short and long term stability of the virus formulations described herein (again, including but not limited to an adenovirus, including a recombinant adenovirus containing a transgene, or portion thereof, which is useful in gene therapy and/or gene vaccination technology). Therefore, a preferred embodiment of the present invention is a viral formulation which contains one or more components which act as an inhibitor of free radical oxidation. It is shown herein that addition of these components enhance long term stability at temperatures up through the 2-8° C.
  • the present invention relates to a virus formulation which contains at least one inhibitor of free radical oxidation which effectively enhances stability of the virus-containing formulation. While the exemplified adenovirus-based formulations such as A113 represent a preferred formulation, these formulations in no way suggest a limitation to additional formulations and methods of use based on alternative formulations components.
  • a third core embodiment of the present invention comprises inclusion, alone or in combination with free radical oxidation inhibitors, an effective amount of plasmid DNA, which is shown to effectively increase the long term stability of a virus formulation and conditions as described throughout this specification. Therefore, the present invention also relates to a virus formulation which contains an amount of a nucleic acid such that addition of the nucleic acid effectively enhances stability of the virus-containing formulation.
  • FIG. 1 shows the effects of one freeze/thaw cycle (from ⁇ 70° C. to 5° C.) on the recovery/stability of Ad5gag in formulations A101 through A107.
  • FIG. 2 shows the effect of 1 to 3 freeze/thaw cycles on the recovery/stability of Ad5gag in formulations A101 through A107.
  • FIG. 3 shows the loss of infectivity of Ad5gag in formulations A101 through A107.
  • FIG. 4 shows the effect of 12 freeze/thaw cycles on the stability of Ad5gag in A105 at 10 8 , 10 10 and 10 11 vp/mL.
  • FIG. 5 shows the effect that freezing, thawing and a 15° C. incubation have on the infectivity of Ad5gag in A105.
  • FIG. 6 shows short-term stability (72 hours) of Ad5gag in formulations A102, A105, A106 and A107 at 1 ⁇ 10 7 vp/nL and 1 ⁇ 10 9 vp/nL.
  • FIG. 7 shows short-term stability (up to 28 days) of Ad5gag in formulations A105, A106 and A107 at 2-8° C.
  • FIG. 8 shows short-term stability (up to 28 days) of Ad5gag in formulations A105, A106 and A107 at 15° C.
  • FIG. 9 shows short-term stability (up to 28 days) of Ad5gag in formulations A105, A106 and A107 at 25° C.
  • FIG. 10 shows short-term stability (up to 28 days) of Ad5gag in formulations A105, A106 and A107 at 37° C.
  • FIG. 11 shows an Arrhenius plot of Ad5gag inactivation at pH 7.4 and pH 8.6.
  • FIG. 12 shows the effect of pH on Ad5gag infectivity at 2-8° C., 15° C. and 25° C.
  • FIG. 13 shows the effect of pH on the long-term stability (up to 12 months) of Ad5gag at 15° C. and 25° C.
  • FIG. 14 shows the effect of pH on the long-term stability (12 months) of Ad5gag at 2-8° C.
  • FIG. 15 shows the effect of MgCl 2 on Ad5gag stability at 2-8° C., 15° C. and 30° C.
  • FIG. 16 shows the effect of MgCl 2 concentration on Ad5gag stability at 30° C.
  • FIG. 17 shows the effect of polysorbate-80 (PS-80) on the stability of Ad5gag at 2-8° C., 15° C. and 30° C.
  • FIG. 18 shows the effect of polysorbate-80 (PS-80) concentration on the stability of Ad5gag at 2-8° C., 15° C. and 30° C.
  • FIG. 19 shows the effect of polysorbate-80 (PS-80) concentration on the stability of Ad5gag at 25° C. and 30° C. for one month.
  • FIG. 20 shows the effect of polysorbate type (PS-80 and PS-40) on the stability of Ad5gag at 25° C. and 30° C.
  • FIG. 21 shows the effect of virus concentration on stability at 37° C.
  • FIG. 22 shows the effect of ascorbic acid and iron on Ad5gag stability.
  • FIG. 23 shows the effect of oxidation inhibitors on Ad5gag stability at 2-8° C., 15° C. and 30° C.
  • FIG. 24 shows the stability of Ad5gag at ⁇ 70° C. and ⁇ 15° C., between 10 7 and 10 9 vp/mL.
  • FIG. 25 shows the stability of Ad5gag in A105 at ⁇ 70° C. at 10 9 vp/mL and 10 11 vp/mL.
  • FIG. 26 shows the stability of Ad5gag in A105 at ⁇ 15° C. at 10 9 vp/mL and 10 11 vp/mL.
  • FIG. 27 shows the effect of combining PS-80 and EDTA/Ethanol on Ad5gag stability at 25° C. and 30° C. for 1 month.
  • FIG. 28 shows the effect of various oxidations inhibitors on Ad5gag stability at 1 and 2 months at 30° C. as shown with formulations A113, A132, A133, A134, A135, A136 and A137.
  • FIG. 29 shows the long-term stability of Ad5gag in selected formulations after 18 months of storage at 2-8° C.
  • FIG. 30 shows the long-term stability of Ad5gag in additional selected formulations after one year of storage at 2-8° C.
  • FIG. 31 shows the stability of Ad5gag in selected formulations after 9 months of storage at 2-8° C. and 15° C.
  • FIG. 32 shows the stability of Ad5gag in selected formulations of the present invention compared to Ad5gag stability in formulations disclosed by Transgene and Schering-Plough, after 9 months of storage at 2-8° C. and 15° C.
  • the present invention relates to formulations which stabilize a respective virus component and to related pharmaceutical products, preferably for use in gene therapy and/or vaccine applications.
  • a preferred stabilized virus containing formulation disclosed herein is liquid adenovirus formulation, which shows improved stability when stored in about the 2-8° C. range and higher while also being compatible with parenteral administration.
  • a respective virus such as a recombinant adenovirus
  • a respective virus may comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as additional components which enhance stability to the added virus, including but not limited to a free radical scavenger and/or a chelating agent (i.e., an inhibitor of free radical oxidation).
  • a free radical scavenger i.e., an inhibitor of free radical oxidation
  • a chelating agent i.e., an inhibitor of free radical oxidation
  • the formulations which comprise various concetrations of adenovirus are amenable to prolonged storage at 2° C. to 8° C. and higher for periods up to at least one to two years.
  • the virus formulations which may show enhanced long term storage stability include but are not necessarily limited to adenovirus, adeno-associated virus, retroviruses, herpes virus, vaccinia virus, rotovirus, pox viruses.
  • the preferred virus is a human adenovirus, especially a serotype from a subgroup which shows negligible or no tumor growth in animals, such as subgroup C (Ad1, Ad2, Ad5 and Ad6), subgroup D (Ad8, Ad9, Ad10, Ad13, Ad15, Ad17, Ad19, Ad20, Ad22, Ad23, Ad24, Ad25, Ad26, Ad27, Ad28, Ad29, Ad30, Ad32, Ad33, Ad36, Ad37, Ad38, Ad39, Ad42, Ad43, Ad44, Ad45, Ad46, and Ad4) and subgroup E (Ad4).
  • subgroup C Ad1, Ad2, Ad5 and Ad6
  • subgroup D Ad8, Ad9, Ad10, Ad13, Ad15, Ad17, Ad19, Ad20
  • adenovirus classification scheme see Fundamental Virology, 3 rd Edition, Ch. 30 @ page 980, Ed. Fields, et al. 1996, Lippincott-Raven.
  • serotypes are selected C serotypes Ad5, Ad2, and Ad6 and subgroup D serotype Ad24.
  • the skilled artisan may adapt the formulations dislcosed herein to non-exemplified adenovirus serotyoes as well as other viruses.
  • the present invention relates to the use of these formulations to stabilize alternative purified virus, and to the compositions thereof.
  • the formulations of the present invention provide stability to adenovirus at varying degrees of virus concentration and may be administered to a variety of vertebrate organisms, preferably mammals and especially humans.
  • the stabilized viral formulations of the present invention are preferably recombinant adenovirus-based compositions, wherein administed as a vaccine, for example, may offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of a particular microbial infection, such as an HIV infection.
  • a preferred aspect of the invention is a recombinant adenovirus formulation (i.e., an adenovirus containing a whole or a portion of a transgene which is expressed within the target host subsequent to host administration, such as in any mammalian/human gene therapy- or gene vaccination-based methodology available to the skilled artisan) which shows enhanced stability characteristics described herein with a virus concentration in the range from about 1 ⁇ 10 7 vp/mL (virus particles/millileter) to about 1 ⁇ 10 13 vp/mL.
  • a more preferred range is from about 1 ⁇ 10 9 to 1 ⁇ 10 12 vp/mL, with an especially preferred virus concentration being from about 1 ⁇ 10 11 to 1 ⁇ 10 12 vp/mL.
  • compositions of the formulations of the present invention are administered to an individual in amounts sufficient to treat, prevent or diagnose the respective disorder.
  • the effective amount for human administration may, of course, vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
  • the amount of expressible DNA to be administered to a human recipient will depend on the strength of the transcriptional and translational promoters used in the recombinant viral construct, and, if used as a vaccine, on the immunogenicity of the expressed gene product, as well as the level of pre-existing immunity to a virus such as adenovirus.
  • the formulations of the present invention are optimally a buffered solution.
  • virus formulations of the present invention in a physiologically acceptable buffer, preferably but not necessarily limited to a formulation buffered with Tris (tromethamine), histidine, phosphate, citrate, succinate, acetate, glycine, and borate, within a pH range including but not limited to about 7.0 to about 9.0, preferably a pH range from about 7.5 to about 8.5. Tris is preferred in the exemplified formulations disclosed herein.
  • An additional aspect of the formulations of the present invention relates to a formulation which comprises a minimal amount of at least one non-ionic surfactant added to reduce adsorption to container surfaces as well as possibly providing increased virus stabilization.
  • Non-ionic surfactants for use in the formulations of the present invention include but are not limited to polyoxyethylene sorbitan fatty acid esters, including but not limited to Polysorbate-80 (Tween 80®), Polysorbate-60 (Tween 60®), Polysorbate-40 (Tween 40®) and Polysorbate-20 (Tween 20®), polyoxyethylene alkyl ethers, including but not limited to Brij 58®, Brij 35®, as well as others such as Triton X-100®, Triton X-114®, NP40®, Span 85 and the Pluronic series of non-ionic surfactants (e.g., Pluronic 121).
  • An additional component which further stabilizes the added viral component comprise the addition of at least one salt of a divalent cation, including but not necessarily limited to MgCl 2 , CaCl 2 and MnCl 2 .
  • the preferred divalent cations are MgCl 2 and CaCl 2 at a concentration ranging from about 0.1 mM to about 5 mM.
  • cryoprotectant Another component which contributes to virus stabilization over large temperature ranges and for prolonged storage periods is a cryoprotectant, especially at concentrations amenable to human administration.
  • Cyroprotectants include but are not necessarily limited to addition of polyhydroxy hydrocarbons such as sorbitol, mannitol, glycerol and dulcitol and/or disaccharides such as sucrose, lactose, maltose or trehalose.
  • An additional component of the formulations of the present invention which enhance viral stability comprise a salt, including but not necessarily limited to sodium chloride, sodium sulfate, and ammonium sulfate, present at an ionic strength which is physiologically acceptable to the host.
  • a salt including but not necessarily limited to sodium chloride, sodium sulfate, and ammonium sulfate, present at an ionic strength which is physiologically acceptable to the host.
  • a purpose of inclusion of a salt in the formulation is to attain the desired ionic strength or osmolarity. Contributions to ionic strength may come from ions produced by the buffering compound as well as from the ions of non-buffering salts.
  • a centerpiece of the formulations of the present invention which enhance viral stability relate to inclusion of components that act as inhibitors of free radical oxidation.
  • virus stability in a pharmaceutical formulation may be effected by the type of buffer, salt concentration, pH, light exposure, temperature storage and the such. It is also shown herein that components which may inhibit free radical oxidation further enhance the stability characteristics of the core adenoviral formulations disclosed herein.
  • Free radical oxidation inhibitors which may be utilized include but are not necessarily limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (TEOA), mannitol, histidine, glycerol, sodium citrate, inositol bexaphosphate, tripolyphosphate, succinic and malic acid, desferal, ethylenediamine-Di(o-hydoxy-phenylacetic acid (EDDHA) and diethylenetriaminepenta-acetic acid (DTPA), or specific combinations thereof. It is preferred that the inhibitor of free radical oxidation be either an EDTA/EtOH combination, EtOH alone, or triethanolamine (TEOA).
  • the combination with other components may determine the effectiveness of the free radical oxidation inhibitor.
  • the combination of EDTA/EtOH is shown to be very effective at increasing stability, while DTPA (alone) in the absence of MgCl 2 also enhances stability. Therefore, the skilled artisan may “mix and match” various components, in some cases a scavenger and a chelator are required, while other formulations only a chelator may be required. Preferably, the choice of chelator will determine whether or not the addition of a scavenger is needed. Additional free radical scavengers and chelators are known in the art and apply to the formulations and methods of use described herein.
  • the formulations of the present invention which enhance viral stability rely on a useful range of total osmolarity which both promotes long term stability at temperature of 2-8° C., or higher, while also making the formulation useful for parenteral, and especially intramuscular, injection.
  • the effective range of total osmolarity (the total number of molecules in solution) is from about 200 mOs/L to about 800 mOs/L, with a preferred range from about 250 mOs/L to about 450 mOs/L.
  • An especially preferred osmolarity for the formulations disclosed herein is about 300 mOs/L.
  • a salt free formulation may contain from about 5% to about 25% sucrose, with a preferred range of sucrose from about 7% to about 15%, with an especially preferred sucrose concentration in a salt free formulation being from 10% to 12%.
  • a salt free sorbitol-based formulation may contain sorbitol within a range from about 3% to about 12%, with a preferred range from about 4% to 7%, and an especially preferred range is from about 5% to about 6% sorbitol in a salt-free formulation.
  • Salt-free formulations will of course warrant increased ranges of the respective cryoprotectant in order to maintain effective osmolarity levels.
  • an effective range of a sucrose-based solution in 75 mM NaCl is from about 2% about 7.5% sucrose, while a sorbitol-based solution in 75 mM NaCl is from about 1% to about 4% sorbitol.
  • the present invention relates to a formulation containing an adenovirus, such as a recombinant adenovirus for use in gene therapy and/or gene vaccination applications, with show increased viral stability properties and which at least contain a buffer, a salt, a sugar and a surfactant.
  • an adenovirus such as a recombinant adenovirus for use in gene therapy and/or gene vaccination applications, with show increased viral stability properties and which at least contain a buffer, a salt, a sugar and a surfactant.
  • a particular embodiment of the present invention relates to such a recombinant adenovirus formulation which comprises Tris as the buffer, sucrose as the cryoprotectant, NaCl as the salt, MgCl 2 as the divalent cation and either Polysorbate-80 or Polysorbate40 as the surfactant.
  • the formulation is buffered with Tris to a range from about pH 7.5 to about pH 8.5; sucrose is added within a range upwards of a weight to volume percentage of 10, depending upon the salt concentration; the salt being NaCl which is added at concentration within a range of upwards of 250 mM NaCl, complementing the sucrose concentration such that total osmolarity ranges from about 200 mOs/L to about 800 mOs/L; the divalent cation is MgCl 2 in a range from about 0.1 mM to about 10 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 1% or Polysorbate-40 at a concentration from about 0.001% to about 1%.
  • the formulation is buffered with about 1 mM to about 10 mM Tris to a range from about pH 7.5 to about pH 8.5; sucrose is present in a weight to volume range of about 2% to about 8% and NaCl is present from a range of about 25 mM to about 250 mM, the sucrose and NaCl concentrations being complementary such that the total osmolarity ranges from about 200 mOs/L to about 800 mOs/L; the divalent cation is MgCl 2 in a range from about 0.1 mM to about 5 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.25% or Polysorbate40 at a concentration from about 0.001% to 0.25%.
  • the formulation is buffered with about 2.5 mM to about 7.5 mM Tris to a pH of about 8.0; sucrose is present in a weight to volume range of about 2% to about 8% and NaCl is present from a range of about 25 mM to about 250 mM, the sucrose and NaCl contributing to a total osmolarity range from about 250 mOs/L to about 450 mOs/L; the divalent cation is MgCl 2 in a range from about 0.5 mM to about 2.5 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.1% or Polysorbate40 at a concentration from about 0.001% to 0.1%.
  • the formulation is buffered with about 5.0 mM Tris to a pH of about 8.0; sucrose is present in a weight to volume range of about 4% to about 6% and NaCl is present from a range of about 50 mM to about 100 mM, the sucrose and NaCl contributing to a total osmolarity range from about 250 mOs/L to about 450 mOs/L; the divalent cation is MgCl 2 in a range from about 1 mM to about 2 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.1% or Polysorbate-40 at a concentration from about 0.001% to 0.1%.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of about 5%; NaCl is present at about 75 mM, with the total osmolarity at about 300 mOs/L; MgCl 2 in at about 1 mM to 2 mM, and either Polysorbate-80 is present at a concentration of about 0.02% or Polysorbate-40 at a concentration of about 0.005%.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 310 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%.
  • This formulation is herein designated A105.
  • PS-80 ranges to at least 0.1%, as opposed to A105, where PS-80 is found at 0.005%.
  • This formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, MgCl 2 is at 1 mM, and Polysorbate-80 is present at a concentration of 0.1%.
  • This formulation is herein designated A111.
  • Another embodiment of the present invention is exemplified by a formulation buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, MgCl 2 at 1 mM, and Polysorbate-40 is present at a concentration of 0.005%.
  • This formulation is herein designated A128, as shown in Example 1.
  • the present invention further relates recombinant adenovirus formulations which omit at least one component of the above-disclosed component, including but not limited to formulation A108 (no divalent cation) or formulation A109 (no surfactant).
  • An essential quality of the present invention is the finding that non-reducing free radical scavengers and/or chelators are important for maximizing both short and long term stability of viral formulations, especially recombinant adenoviral formulations disclosed herein.
  • a critical preferred embodiment of the present invention is a viral formulation which contains one or more components which act as an inhibitor of free radical oxidation. It is shown herein that addition of these components enhance long term stability at temperatures up through the 2-8° C. range, or higher, when compared to core formulations which do not contains these inhibitors. In addition, these formulations are compatible with parenteral administration. The increased stability of these formulations shows that oxidation is a major pathway of adenovirus inactivation which results in a loss of infectivity during storage.
  • the present invention relates to a recombinant adenoviral formulation buffered with Tris to a range from about pH 7.5 to about pH 8.5; sucrose is added within a range upwards of a weight to volume percentage of 10, depending upon the salt concentration; the salt being NaCl which is added at concentration within a range of upwards of 250 mM NaCl, complementing the sucrose concentration such that total osmolarity ranges from about 200 mOs/L to about 800 mOs/L; the divalent cation is MgCl 2 in a range from about 0.1 mM to about 10 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 2% or Polysorbate-40 at a concentration from about 0.001% to about 1%, wherein the formulation further comprises one or more components described herein which inhibit free radical oxidation, including but not limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (EtOH
  • the formulation is buffered with about 1 mM to about 10 mM Tris to a range from about pH 7.5 to about pH 8.5; sucrose is present in a weight to volume range of about 2% to about 8% and NaCl is present from a range of about 25 mM to about 250 mM, the sucrose and NaCl concentrations being complementary such that the total osmolarity ranges from about 200 mOs/L to about 800 mOs/L; the divalent cation is MgCl 2 in a range from about 0.1 mM to about 5 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.25% or Polysorbate-40 at a concentration from about 0.001% to 0.5%, wherein the formulation further comprises one or more components described herein which inhibit free radical oxidation, including but not limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (EtOH), EDTA, an EDTA
  • the formulation is buffered with about 2.5 mM to about 7.5 mM Tris to a pH of about 8.0; sucrose is present in a weight to volume range of about 2% to about 8% and NaCl is present from a range of about 25 mM to about 250 mM, the sucrose and NaCl contributing to a total osmolarity range from about 250 mOs/L to about 450 mOs/L; the divalent cation is MgCl 2 in a range from about 0.5 mM to about 2.5 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.1% or Polysorbate-40 at a concentration from about 0.001% to 0.05%, wherein the formulation further comprises one or more components described herein which inhibit free radical oxidation, including but not limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (TEOA), mannitol
  • EtOH ethanol
  • EDTA an
  • the formulation is buffered with about 5.0 mM Tris to a pH of about 8.0; sucrose is present in a weight to volume range of about 4% to about 6% and NaCl is present from a range of about 50 mM to about 100 mM, the sucrose and NaCl contributing to a total osmolarity range from about 250 mOs/L to about 450 mOs/L; the divalent cation is MgCl 2 in a range from about 1 mM to about 2 mM, and the surfactant is either Polysorbate-80 at a concentration from about 0.001% to about 0.1% or Polysorbate40 at a concentration from about 0.001% to 0.01%, wherein the formulation further comprises one or more components described herein which inhibit free radical oxidation, including but not limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (TEOA), mannitol, histidine, glyce
  • EtOH ethanol
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of about 5%; NaCl is present at about 75 mM, with the total osmolarity at about 300 mOs/L; MgCl 2 in at about 1 mM, and either Polysorbate-80 is present at a concentration of about 0.02% or Polysorbate-40 at a concentration of about 0.005%, wherein the formulation further comprises one or more components described herein which inhibit free radical oxidation, including but not limited to ethanol (EtOH), EDTA, an EDTA/ethanol combination, triethanolamine (TEOA), mannitol, histidine, glycerol, sodium citrate, inositol hexaphosphate, tripolyphosphate, succinic and malic acid, desferal, ethylenediamine-Di(o-hydoxy-phenylacetic acid (EDDHA)
  • At least one non-reducing free radical scavenger may be added to concentrations which effectively enhance stability of the core formulation.
  • Especially useful ranges include (i) EDTA from about 1 ⁇ M to about 500 ⁇ M, preferably in a range from about 50 ⁇ M to about 250 ⁇ M, and an especially preferred concentration of at or around 100 ⁇ M; (ii) ethanol from about 0.1% to about 5.0%, preferably in a range from about 0.25% to about 2.0%, and an especially preferred amount totaling at or around 0.5%; (iii) DTPA from about 1 ⁇ M to about 500 ⁇ M, preferably in a range from about 50 , ⁇ M to about 250 ⁇ M, and an especially preferred concentration at or around 100 ⁇ M; (iv) CaCl 2 from about 0.1 mM to about 10 mM, preferably in a range from about 0.5 mM to about 5 mM, and an especially preferred concentration at or around 1 M; and, (v)
  • inhibitors of free radical oxidation may also be added in various combinations, including but not limited to two scavengers (e.g., 113), a sole (e.g., A114), or possible a sole scavenger in the absence of another component, such as a divalent cation (e.g., A116).
  • two scavengers e.g., 113
  • a sole e.g., A114
  • a sole scavenger in the absence of another component, such as a divalent cation (e.g., A116).
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/l; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M and ethanol at 0.5%.
  • This formulation is designated A113, as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 310 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, and triethanolamine (TEOA) is present at 1 mM.
  • This formulation is herein designated A114, as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 350 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, and sodium citrate at 10 mM.
  • This formulation is herein designated A115, also as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, Polysorbate-80 is present at a concentration of 0.005%, and DTPA at 100 ⁇ M.
  • This formulation is herein designated A116, also as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris-HCI, at pH 8.0; sucrose is present in a weight to volume range of 5% (146 mM); NaCl is present at 75 mM, MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, and mannitol is present at 3% (w/v).
  • This formulation is herein designated A121.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, MgCl 2 at 1 mM, Polysorbate-80 is present at a concentration of 0.005%, and ethanol is present at a concentration of 0.5% (A132) and 1.0% (A134).
  • Another embodiment shows a formulation buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 310 mOs/L; MgCl 2 at 1 mM, Polysorbate-80 is present at a concentration of 0.005%, and EDTA at 100 ⁇ M.
  • This formulation is herein designated A133, also as shown in Example 1.
  • Another preferred embodiment shows a formulation buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 500 mOs/L; MgCl 2 at 1 mM, Polysorbate-80 is present at a concentration of 0.005%, EDTA at 100 ⁇ M and ethanol 1.0%.
  • This formulation is herein designated A135, also as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 1 mM, Polysorbate-80 is present at a concentration of 0.1%, EDTA at 100 ⁇ M and ethanol 0.5%.
  • This formulation is herein designated A136, also shown in Example 1.
  • a preferred divalent cation such as MgCl 2 with a difference divalent cation, CaCl 2 .
  • Such a substitution may relate to any of the formulations disclosed herein.
  • An example of such a substitution is formulation A120, which comprises 5.0 mM Tris-HCl, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, Polysorbate-80 at 0.005%, EDTA at 100 ⁇ M, ethanol at 0.5% and CaCl 2 at 1 mM.
  • Formulation A120 is shown in Example 1.
  • the present invention further relates recombinant adenovirus formulations which omit at least one component of the above-disclosed components, including but not limited to formulation A116 (excipient: DTPA at 100 ⁇ M; no divalent cation), formulation A117 (excipients: EDTA at 100 ⁇ M and EtOH at 0.5%; no divalent cation), formulation A118 (triethanolamine at 1.0 mM; no divalent cation), formulation A119 (excipient: sodium citrate at 10 mM; no divalent cation).
  • formulation A116 excipient: DTPA at 100 ⁇ M; no divalent cation
  • formulation A117 excipients: EDTA at 100 ⁇ M and EtOH at 0.5%
  • formulation A118 triethanolamine at 1.0 mM; no divalent cation
  • formulation A119 excipient: sodium citrate at 10 mM; no divalent cation.
  • the present invention further relates to a recombinant viral formulation which additionally comprises plasmid DNA at a concentration from about 0.01 mg/ml to about 10 mg/ml.
  • plasmid DNA effectively increases the stability of a recombinant virus formulation, such as the recombinant adenovirus exemplified herein. Therefore, plasmid DNA may be added to any core formulations (e.g., A105 and A128, which do not contain additional excipients such as free radical oxidation inhibitors), as well as core formulations comprising such excipients.
  • a preferred concentration range for the plasmid DNA is from about 0.5 mg/l to about 5.0 mg/ml, with an additionally preferred plasmid DNA concentration at 1 mg/ml.
  • the formulation is buffered with about 5.0 mM Tris-HCl, at pH 8.0; sucrose is present in a weight to volume range of 5% (146 mM); NaCl is present at 75 mM, MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, and plasmid DNA is present at 1 mg/ml.
  • This formulation is herein designated A137.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M, ethanol is present at 0.5% and plasmid DNA is present at 1 mg/mL.
  • This formulation is designated A138, as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 8.0; mannitol is present in a weight to volume of 2.7% (147 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M and ethanol at 0.5%.
  • This formulation is designated A149, as shown in Example 1.
  • Another embodiment shows a formulation buffered with about 5.0 mM Tris, at pH 8.0; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M, ethanol is present at 0.5% and histidine is present at 5 mM.
  • This formulation is designated A151a, as shown in Example 1.
  • Another embodiment of the present invention disclosed a formulation buffered with about 5.0 mM Tris, at pH 7.5 at 30° C.; while sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 1 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M, ethanol is present at 0.5% and histidine is present at 5 mM.
  • This formulation is designated A151b, as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 7.5 at 30° C.; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 2 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M, ethanol is present at 0.5%, histidine is present at 5 mM and triethanolamine is present at 5 mM.
  • This formulation is designated A152, as shown in Example 1.
  • the formulation is buffered with about 5.0 mM Tris, at pH 7.5 at 30° C.; sucrose is present in a weight to volume of 5% (146 mM); NaCl is present at 75 mM, with the total osmolarity approximately 400 mOs/L; MgCl 2 at 2 mM, and Polysorbate-80 is present at a concentration of 0.005%, EDTA is present at 100 ⁇ M, ethanol is present at 0.5%, histidine is present at 5 mM, triethanolamine is present at 5 mM and glycerol is present at 5% (v/v).
  • This formulation is designated A153, as shown in Example 1.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, level of pre-existing immunity to adenovirus, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the formulated recombinant viruses described herein may also be formulated with an adjuvant or adjuvants which may increase immunogenicity of the expressed transgene.
  • adjuvants are known in the art and are available for use, including but not limited to saponin, monophosphoryl lipid A, non-ionic block copolymers composed of polyoxyethylene and polyoxypropylene or other compounds which increase immunogenicity of expressed transgene.
  • Another adjuvant for use with the recombinant viruses described herein are one or more forms of an aluminum phosphate-based adjuvant wherein the aluminum phosphate-based adjuvant possesses a molar PO 4 /Al ratio of approximately 0.9.
  • An additional mineral-based adjuvant may be generated from one or more forms of a calcium phosphate.
  • These mineral-based compounds for use as DNA vaccines adjuvants are disclosed in PCT International Application No. PCT/US98/02414 (WO 98/35562), which is hereby incorporated by reference.
  • the recombinant virus formulations described herein are administered to the vertebrate host (preferably a mammalian host and especially a human recipient) by any means known in the art, such as enteral and parenteral routes.
  • routes of delivery include but are not limited to intramuscular injection, intraperitoneal injection, intravenous injection, inhalation or intranasal delivery, oral delivery, sublingual administration, subcutaneous administration, transdermal administration, transcutaneous administration, percutaneous administration or any form of particle bombardment, such as a biolostic device such as a “gene gun” or by any available needle-free injection device.
  • the preferred methods of delivery of the recombinant viruses described herein are intramuscular injection and needle-free injection. An especially preferred method is intramuscular delivery.
  • the present invention also relates to methods of stabilizing virus formulation which comprises generating virus-containing formulations disclosed herein, such formulations which result in improved viral stability when stored in about the 2-8° C. range and higher while also being compatible with parenteral administration, especially patenteral administration to humans. Therefore, these prescribed methods relate to the disclosed, and especially, the exemplified virus-containing formulations of the present invention.
  • the present invention relates to a method of stabilizing a virus formulation which comprises adding at least one inhibitor of free radical oxidation to the formulation, such that the resultant formulation shows improved stability in about the 2-8° C. range and higher while also being compatible with parenteral administration.
  • the present invention relates to a method of stabilizing a virus formulation which comprises adding a nucleic acid to the formulation, such that the resultant formulation also shows improved stability in about the 2-8° C. range and higher while also being compatible with parenteral administration. Therefore, the present invention relates to a method of stabilizing a virus formulation which comprises preserving the virus of interest, preferably a recombinant virus, in any of the formulations described herein, and especially methods which comprise preservation of the virus by addition of at least one one inhibitor of free radical oxidation and/or addition a nucleic acid to the formulation, such that the resultant formulation also shows improved stability in about the 2-8° C. range and higher while also being compatible with parenteral administration.
  • Ad5gag FL HIV-gag transgene
  • TCID50 Adenovirus Infectivity Assay is a method for titrating the infectivity of adenovirus, using a TCID 50 end-point dilution method in a 96-well format. Cells in each well of the 96-well plate that are infected with adenovirus are revealed using a vital staining method based on the Tetrazolium dye (MTS). The amount of color formation per well is correlated with the quantity of living cells, which reflects the extent of adenovirus replication.
  • TMS Tetrazolium dye
  • QPA Adenovirus Infectivity Assay The QPA assay is a procedure for the rapid quantitation of adenovirus infectivity based on the use of Q-PCR technology to quantitate accumulated adenoviral genomes 24 hours after infection of cells.
  • Formulation numbers represent exemplified formulations which, along with accompanying stability data, support the claims appended hereto.
  • Form. # Description A101 10 mM Tris, 10% glycerol (v/v), 1 mM MgCl 2 , pH 7.5 A102 6 mM phosphate, 150 mM NaCl, 10% glycerol (v/v), pH 7.2 A103 6 mM phosphate, 150 mM NaCl, pH 7.2 A104 5 mM Tris, 150 mM NaCl, 1 mM MgCl 2 , 0.005% PS-80, pH 8.0 A105 5 mM Tris, 75 mM NaCl, 5% sucrose (w/v), 1 mM MgCl 2 , 0.005% PS-80, pH 8.0 A106 5 mM Tris, 14% sucrose (w/v), 1 mM MgCl 2 , 0.005% PS-80, pH 8.0 A107 5 mM Tris
  • FIG. 1 shows the effects of one freeze/thaw cycle (from ⁇ 70° C. to 5° C.) on the recovery/stability of Ad5gag in the initial seven formulations, as measured by the QPA assay.
  • the results indicate that Ad5gag lost significant amounts of infectivity, or was adsorbed to the glass vial, in the two formulations that did not contain a cryoprotectant (A103 and A104).
  • a freeze/thaw study was also preformed to determine the effect of freezing and thawing a large aliquot of Ad5gag in A105, to simulate the handling of clinical bulks prior to filling.
  • 600 mL of Ad5gag in A105 at 10 8 vp/mL was frozen at ⁇ 70° C.
  • the sample was then thawed at 2-8° C. and assayed for infectivity by QPA.
  • the aliquot was incubated further at 15° C. for 20 hours, to simulate handling of clinical materials during a filling operation, then assayed again.
  • the results shown in FIG. 5 indicate that the freezing, thawing and 15° C. incubation did not have a significant affect on the infectivity of Ad5gag in A105.
  • Ad5gag in A102, A105, A106 and A107 was also determined at both 10 7 and 10 9 vp/mL by QPA after 6 months of storage at ⁇ 15° C.
  • Ad5gag was formulated in a buffer containing 75 mM NaCl, 5% sucrose, 1 M MgCl 2 , 0.005% PS-80 and either 20 mM Tris or 20 mM Bis-tris-propane as the buffer.
  • the Tris buffered solutions were adjusted to pH 8.6 at each temperature (37, 30, 25 and 15° C.) while the Bis-tris-propane buffered formulations were adjusted to pH 7.4.
  • Ad5gag was formulated at 10 9 and 10 11 vp/mL in A105 and placed on stability at 37° C. Infectivity was determined after 3, 7, 10, 14 and 21 days. The results, shown in FIG. 21, clearly indicate that Ad5gag concentration did not have a significant effect of stability at 37° C.
  • Ad5gag is very susceptible to free radical oxidation induced by both ascorbic acid (in A125) and iron. These results also suggested that it was likely that free radical oxidation may be a major mechanism of inactivation for Ad5gag in A105.
  • Ad5gag in A105 is an acceptable frozen liquid formulation for storage at either ⁇ 70° C. or ⁇ 15° C. (see FIG. 24). Moreover, the stability of Ad5gag in A105 is higher than in any of the other initial candidate formulations (A102-A104, A106, A107). The loss of Ad5gag infectivity in A105 at 2-8° C. will be approximately 0.37-0.44 logs/year, suggesting that further improvements in recombinant adenovirus stability are warranted.
  • Table 1 shows the estimated rate of infectivity loss of exemplified adenoviral formulations.
  • the rate of infectivity loss of various formulations is shown, based on 6 months of stability data at both 2-8° C. and 15° C. Although the 2-8° C. stability data was generated at the intended storage condition the infectivity losses were very small and difficult to measure accurately. Therefore, the rate of infectivity loss was also estimated from an extrapolation of the 15° C. stability data and the activation energy for Ad5gag inactivation using the pH 7.4 pathway (the most conservative extrapolation). The slope of the Arrhenius plot for the pH 7.4 inactivation pathway (see FIG.
  • Ad5gag should have a shelf life 3.3 times as long at 5° C. as it does at 15° C.
  • TABLE 2 Estimated rate Estimated rate of infectivity loss of infectivity loss Ad5gag (logs/year) (based (logs/year) (based formulation on 6 month 2-8° C. data) on 6 month 15° C. data) A105 0.37 0.44 A111 0.14 0.18 A113 ⁇ 0.1 0.14 A114 ⁇ 0.1 0.28 A115 0.14 0.36 A116 ⁇ 0.1 0.14 A117 ⁇ 0.1 0.19 A120 ⁇ 0.1 0.13
  • Ad5gag inactivation is a major mechanism of Ad5gag inactivation during storage has paved the way for the design of additional Ad5gag formulations much more stable than Ad5gag in A105.
  • a formulation containing 100 ⁇ M EDTA and 0.5% ethanol in an A105 base shows enhanced stability at 2-8° C. and is an especially preferred formulation of the present invention.
  • FIG. 29 The long-term stability of Ad5gag in twelve different formulations is shown in FIG. 29. These data show the log loss of Ad5gag infectivity after 18 months in storage at 2-8° C. Based on these data the loss of Ad5gag infectivity in A105 was 0.33 logs/year, close to the estimate made in Example 10 above using the data from FIG. 23. These data clearly show that the addition of free radical oxidation inhibitors (in formulations A113, A114, A116-A121) enhance the stability of adenovirus during storage at 2-8° C.
  • Ad5gag in A135 was also found to be more stable than in A105 and A113, suggesting that the optimal concentration of ethanol in A113 may be near 1%.
  • the variability of the QPA assay is ⁇ 0.15 logs it is not clear whether the other tested formulations are more stable than A105.
  • Adenovirus formulations have recently been disclosed in PCT publication number WO 98/02522 (Transgene) and WO 99/41416 (Schering-Plough).
  • WO 98/02522 Transgene
  • WO 99/41416 Stchering-Plough
  • Ad5gag in A105, A111, A113, A136 one formulation from WO 98/02522 (TG#2) and five formulations from WO 99/41416 (SP#1-SP#5), at 10 8 vp/mL, as described below.
  • SP#1 1.7 mg/ml Sodium Phosphate Monobasic Dihydrate, 1.7 mg/ml Tris, 0.4 mg/ml MgCl 2 , 20mg/ml Sucrose, 0.15 mg/ml PS-80, 100 mg/ml Glycerol, pH 7.53;
  • SP#2 1.7 mg/ml Sodium Phosphate Monobasic Dihydrate, 1.7 mg/ml Tris, 0.4 mg/ml MgCl 2 , 20mg/ml Sucrose, 0.15 mg/ml PS-80, 100 mg/ml Glycerol, pH 7.36;
  • SP#3 1.7 mg/ml Sodium Phosphate Monobasic Dihydrate, 1.7 mg/ml Tris, 0.4 mg/ml MgCl2, 20mg/ml Sucrose, 100 mg/ml Glycerol, pH 7.6;
  • SP#4 1.7 mg/ml Sodium Phosphate Monobasic Dihydrate, 1.7 mg/ml Tris, 0.4 mg/ml MgCl2, 20mg/ml Sucrose, 100 mg/ml Glycerol, pH 7.37;
  • SP#5 1.7 mg/ml Sodium Phosphate Monobasic Dihydrate, 1.7 mg/ml Tris, 0.4 mg/ml MgCl2, 20mg/ml Sucrose, 5.8 mg/ml NaCl, 100 mg/ml Glycerol, pH 7.53.
  • FIG. 32 shows the data after 9 months of storage at 2-8° C. and 15° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US09/799,937 2000-03-07 2001-03-06 Adenovirus formulations Abandoned US20020041884A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/799,937 US20020041884A1 (en) 2000-03-07 2001-03-06 Adenovirus formulations
US10/791,503 US7351415B2 (en) 2000-03-07 2004-03-02 Adenovirus formulations
US11/071,095 US7456009B2 (en) 2000-03-07 2005-03-03 Adenovirus formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18744000P 2000-03-07 2000-03-07
US09/799,937 US20020041884A1 (en) 2000-03-07 2001-03-06 Adenovirus formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/791,503 Continuation US7351415B2 (en) 2000-03-07 2004-03-02 Adenovirus formulations

Publications (1)

Publication Number Publication Date
US20020041884A1 true US20020041884A1 (en) 2002-04-11

Family

ID=22688996

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/799,937 Abandoned US20020041884A1 (en) 2000-03-07 2001-03-06 Adenovirus formulations
US10/791,503 Expired - Lifetime US7351415B2 (en) 2000-03-07 2004-03-02 Adenovirus formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/791,503 Expired - Lifetime US7351415B2 (en) 2000-03-07 2004-03-02 Adenovirus formulations

Country Status (6)

Country Link
US (2) US20020041884A1 (enExample)
EP (2) EP2420247A1 (enExample)
JP (1) JP5118798B2 (enExample)
AU (1) AU4346101A (enExample)
CA (2) CA2799545A1 (enExample)
WO (1) WO2001066137A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
WO2004045513A3 (en) * 2002-11-15 2004-07-22 Genvec Inc Coronary artery disease treatment
WO2004045645A3 (en) * 2002-11-15 2004-07-29 Janusz Boratynski A bacteriophage preparation of enhanced stability by application of a block copolymer of ethylene oxide and propylene oxide
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CN110300591A (zh) * 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
US20210163990A1 (en) * 2018-07-11 2021-06-03 Baxalta Incorporated Aav compositions
CN113750227A (zh) * 2020-06-01 2021-12-07 康希诺生物股份公司 一种SARS-CoV-2疫苗
US11911440B2 (en) 2009-05-02 2024-02-27 Genzyme Corporation Gene therapy for neurodegenerative disorders
WO2025045082A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技（杭州）有限公司 一种缓冲系统及其相应液体制剂及其用途
EP4424705A4 (en) * 2021-10-29 2026-02-18 Agc Inc Composition for adding cells

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
DK1585548T3 (en) * 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
ATE555127T1 (de) * 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
ES2932278T3 (es) * 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN111514314A (zh) * 2013-09-19 2020-08-11 扬森疫苗与预防公司 改进的腺病毒配制品
EP3082769B1 (en) * 2013-12-19 2018-01-31 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
CN105267960A (zh) * 2014-06-13 2016-01-27 亚宝药业太原制药有限公司 一种重组腺病毒疫苗制剂及其制备方法
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2018204677A1 (en) * 2017-05-04 2018-11-08 Epicentrx, Inc. Oncolytic adenovirus formulation
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019113202A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
CN113613664B (zh) 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
JP7630443B2 (ja) * 2019-04-19 2025-02-17 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
EP4013436A1 (en) 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
WO2022032104A1 (en) * 2020-08-07 2022-02-10 Janssen Biotech, Inc. Formulations for highly purified viral particles
IL291025B2 (en) * 2020-08-22 2026-03-01 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Pharmaceutical agent for inducing specific immunity against SARS-COV-2
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
IL291822B2 (en) * 2021-02-21 2026-04-01 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Using a rangefinder to recruit specific immunity against severe acute respiratory syndrome SARS-COV-2 for population vaccination (variants)
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
JP4386965B2 (ja) * 1996-04-26 2009-12-16 メルク エンド カンパニー インコーポレーテッド Ｄｎａワクチン製剤
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO1998035562A1 (en) 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
KR100918187B1 (ko) * 1998-02-17 2009-09-22 쉐링 코포레이션 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법
BR9801328A (pt) 1998-03-09 1999-10-05 Cardio Sistemas Comercial E In Equipamento multi-funcional para diagnostico e monitoração da atividade elétrica/cardìaca
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
KR101492396B1 (ko) 2014-09-11 2015-02-13 주식회사 우심시스템 어레이형 잉크 카트리지

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
WO2004045513A3 (en) * 2002-11-15 2004-07-22 Genvec Inc Coronary artery disease treatment
WO2004045645A3 (en) * 2002-11-15 2004-07-29 Janusz Boratynski A bacteriophage preparation of enhanced stability by application of a block copolymer of ethylene oxide and propylene oxide
US11911440B2 (en) 2009-05-02 2024-02-27 Genzyme Corporation Gene therapy for neurodegenerative disorders
US12350311B2 (en) 2009-05-02 2025-07-08 Genzyme Corporation Gene therapy for neurodegenerative disorders
US11975043B2 (en) 2009-05-02 2024-05-07 Genzyme Corporation Gene therapy for neurodegenerative disorders
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US9610309B2 (en) 2010-12-02 2017-04-04 Oncolytics Biotech Inc. Liquid viral formulations
US9610352B2 (en) 2010-12-02 2017-04-04 Oncolytics Biotech Inc. Lyophilized viral formulations
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
CN110300591A (zh) * 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
US11583563B2 (en) * 2016-11-04 2023-02-21 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
US12257277B2 (en) 2016-11-04 2025-03-25 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
US20210163990A1 (en) * 2018-07-11 2021-06-03 Baxalta Incorporated Aav compositions
US12553062B2 (en) * 2018-07-11 2026-02-17 Takeda Pharmaceutical Company Limited AAV compositions
CN113750227A (zh) * 2020-06-01 2021-12-07 康希诺生物股份公司 一种SARS-CoV-2疫苗
EP4159234A4 (en) * 2020-06-01 2024-07-31 Cansino Biologics Inc. VACCINE AGAINST SARS-COV-2
EP4424705A4 (en) * 2021-10-29 2026-02-18 Agc Inc Composition for adding cells
WO2025045082A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技（杭州）有限公司 一种缓冲系统及其相应液体制剂及其用途

Also Published As

Publication number Publication date
CA2399321A1 (en) 2001-09-13
US20040166122A1 (en) 2004-08-26
EP1263461A4 (en) 2009-08-12
WO2001066137A1 (en) 2001-09-13
EP2420247A1 (en) 2012-02-22
JP2003525909A (ja) 2003-09-02
CA2799545A1 (en) 2001-09-13
JP5118798B2 (ja) 2013-01-16
CA2399321C (en) 2013-04-30
EP1263461A1 (en) 2002-12-11
US7351415B2 (en) 2008-04-01
AU4346101A (en) 2001-09-17

Similar Documents

Publication Publication Date Title
US7351415B2 (en) Adenovirus formulations
US7456009B2 (en) Adenovirus formulations
US10722470B2 (en) Pharmaceutical composition comprising an adenoviral vector
Evans et al. Development of stable liquid formulations for adenovirus‐based vaccines
KR102258348B1 (ko) 개선된 아데노바이러스 제형
ES2272053T3 (es) Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
US6514943B2 (en) Method and composition for preserving viruses
EP2968112B1 (en) Stable aqueous formulations of adenovirus vectors
US10206960B2 (en) Stabilisation of viral particles
US11590243B2 (en) Formulation
WO2005052116A2 (en) Preservative-containing virus formulations
WO2015040234A1 (en) Adenovirus formulations
US20040033239A1 (en) Adenovirus formulations
AU2006202389B2 (en) Adenovirus formulations
Fan et al. Persistency of adenoviral-mediated lysostaphin expression in goat mammary glands
CN1961961B (zh) 一种药物制剂及其制备方法
KR20220036909A (ko) 광범위하고 오래 지속되는 인플루엔자 백신

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION